Description

Sinopep-Allsino Bio Pharmaceutical Co.,Ltd. is a biomedical enterprise based in China, actively involved in the comprehensive lifecycle of peptide and small molecule drugs. Its operations span from initial research and development to production, sales, and providing technical support for these therapeutic compounds. The company's diverse product portfolio features a range of pharmaceutical formulations, including injectable thymalfasin and eptifibatide, alogliptin benzoate tablets, and oseltamivir phosphate capsules. Furthermore, it manufactures and supplies active pharmaceutical ingredients (APIs) and their intermediates. Sinopep-Allsino also dedicates efforts to developing medications for significant health challenges such as type 2 diabetes, obesity, and viral infections like coronavirus. In addition to its product offerings, the firm provides extensive drug-related services, which encompass pharmaceutical research, clinical trial management, and assistance with regulatory registration processes. It also operates as a contract development and manufacturing organization (CDMO) and a contract manufacturing organization (CMO), undertaking projects focused on small molecule chemical APIs and intermediates. Established in 2009, Sinopep-Allsino Bio Pharmaceutical Co.,Ltd. has its headquarters situated in Hangzhou, China.